Objective To investigate the efficacy of escitalopram combined with duloxetine in the treatment of depression patients with somatization. Methods A total of 100 depression patients with somatic symptoms in a hospital in Henan Province from October 2019 to December 2020 were randomly divided into control group（n=46） and observation group（n=54）. The patients in the control group were treated with duloxetine

and the patients in the observation group were treated with escitalopram combined with duloxetine. The clinical efficacy

adverse reactions

Short Form-36 Health Status Questionnaire（SF-36） before and after treatment and Health Questionnaire-15（PHQ-15） were compared between the two groups. Results The total effective rate of patients in the observation group was 96.30%

which was lower than that in the control group（80.43%）

and the difference was statistically significant（χ

2

=6.383

P=0.012）. After treatment

the scores of all dimensions of SF-36 in the two groups were higher than those before treatment

and those in the observation group were higher than those in the control group

and the differences were statistically significant（P

<

0.05）. After treatment

the PHQ-15 score of the two groups was lower than that before treatment

and that of the observation group was lower than that of the control group

and the difference was statistically significant（P

<

0.05）. The incidence of adverse reactions in the observation group was 20.37%

which was higher than that in the control group（32.61%）

but the difference was not statistically significant（χ

2

=1.934

P=0.164）. Conclusion Escitalopram combined with duloxetine is effective in the treatment of depression patients with somatization

which is helpful to improve the quality of life and alleviate somatization.